Placental immunopathology and congenital transmission of Zika virus and Trypanosoma cruzi: comparative mechanisms, immune disturbances, and potential co-infection scenarios
- 1Molecular Biology and Virology Laboratory, Faculty of Medicine and Health Sciences, Corporación Universitaria Empresarial Alexander von Humboldt
- 2Department of Microbiology & Immunology, University of Texas Medical Branch (UTMB)
- 3Institute for Human Infections and Immunity (IHII), UTMB
Abstract
Congenital transmission of Zika virus (ZIKV) and Trypanosoma cruzi ( T. cruzi ) remains a major public health concern in the Americas. Both pathogens cross the placental barrier and cause severe neonatal outcomes, yet no confirmed congenital co-infections have been reported, and their combined effects on maternal–fetal health are unknown. Critical gaps persist regarding placental immunopathology, fetal immune programming, and long-term consequences of prenatal exposure. This review synthesizes current evidence on the routes and mechanisms of placental transmission of ZIKV and T. cruzi , their tropism for placental and fetal tissues, and their distinct immunological footprints. We summarize how congenital infection perturbs fetal immune maturation, including dysregulation of type I/type III interferons, Th1-skewed inflammation, altered immune-tolerance pathways involving HLA-G and PD-1/PD-L1 signaling, and early innate imprinting. We review advances in vaccine development (spanning inactivated, DNA, mRNA, subunit, and viral vector platforms) and highlight barriers such as antibody-dependent enhancement in ZIKV vaccines and the scarcity of pregnancy-relevant preclinical models for T. cruzi . Promising candidates with evidence of fetal or maternal protection in animal studies are described. Therapeutic approaches, including antiviral discovery, immunomodulatory strategies, and emerging anti- T. cruzi compounds are also examined. A detailed understanding of the immunopathology of congenital ZIKV and T. cruzi infections is essential to improve diagnostic accuracy, preventive strategies, and maternal–fetal clinical care. Integrated mechanistic and translational research is urgently needed to assess the plausibility of co-infection, identify biomarkers of fetal risk, and guide the development of pregnancy-safe vaccines and therapeutics, particularly in resource-limited, endemic settings.
Related
- Seasonal variations of Triatoma dimidiata demography and Trypanosoma cruzi transmission within its multi-host community in the Yucatan Peninsula, Mexico: Insights from an integrative SIR eco-epidemiological modelling
- Comparative Analysis of Two Real-Time PCR Techniques for the Detection of Congenital Syphilis in Umbilical Cord Blood
- Sleep Disturbances and Health-Related Quality of Life in Paediatric Oncology: A Comparative Study with Non-Oncological Chronic Illness and Healthy Peers.
- Prophylactic Intramedullary Nailing Following Femoral Lengthening in Congenital Femoral Deficiency: A Retrospective Comparative Study
- Comparative Analysis of Classical, Fractional, and Quantum Calculus Models for Measles Transmission Dynamics
BibTeX
@article{rodriguezsalazar2026placental,
title = {{Placental immunopathology and congenital transmission of Zika virus and Trypanosoma cruzi: comparative mechanisms, immune disturbances, and potential co-infection scenarios}},
author = {Carlos Andres Rodriguez-Salazar and Delia Piedad Recalde-Reyes and Nisha J. Garg and Maria I. Giraldo},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1824065},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1824065/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Placental immunopathology and congenital transmission of Zika virus and Trypanosoma cruzi: comparative mechanisms, immune disturbances, and potential co-infection scenarios
AU - Carlos Andres Rodriguez-Salazar
AU - Delia Piedad Recalde-Reyes
AU - Nisha J. Garg
AU - Maria I. Giraldo
PY - 2026
DA - 2026/10/07
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1824065
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1824065/full
AB - Congenital transmission of Zika virus (ZIKV) and Trypanosoma cruzi ( T. cruzi ) remains a major public health concern in the Americas. Both pathogens cross the placental barrier and cause severe neonatal outcomes, yet no confirmed congenital co-infections have been reported, and their combined effects on maternal–fetal health are unknown. Critical gaps persist regarding placental immunopathology, fetal immune programming, and long-term consequences of prenatal exposure. This review synthesizes current evidence on the routes and mechanisms of placental transmission of ZIKV and T. cruzi , their tropism for placental and fetal tissues, and their distinct immunological footprints. We summarize how congenital infection perturbs fetal immune maturation, including dysregulation of type I/type III interferons, Th1-skewed inflammation, altered immune-tolerance pathways involving HLA-G and PD-1/PD-L1 signaling, and early innate imprinting. We review advances in vaccine development (spanning inactivated, DNA, mRNA, subunit, and viral vector platforms) and highlight barriers such as antibody-dependent enhancement in ZIKV vaccines and the scarcity of pregnancy-relevant preclinical models for T. cruzi . Promising candidates with evidence of fetal or maternal protection in animal studies are described. Therapeutic approaches, including antiviral discovery, immunomodulatory strategies, and emerging anti- T. cruzi compounds are also examined. A detailed understanding of the immunopathology of congenital ZIKV and T. cruzi infections is essential to improve diagnostic accuracy, preventive strategies, and maternal–fetal clinical care. Integrated mechanistic and translational research is urgently needed to assess the plausibility of co-infection, identify biomarkers of fetal risk, and guide the development of pregnancy-safe vaccines and therapeutics, particularly in resource-limited, endemic settings.
SN - 1664-3224
ER -